Biotech Events And Company Events
The Optimize 2013: Antibody Engineering & Discovery Conference
When 25 Feb. 2013 to 27 Feb. 2013 Where Maritim Hotel Frankfurt, Theodor-Heuss-Allee, Frankfurt, Germany Introduction With many antibody companies facing shared challenges in discovery and engineering, innovative strategies are emerging to improve existing protocols and drive revolution in
The Biosimilar Industry Emerging Trends in Asia
At the time when biosimilars market development in the U.S. and Europe still looks a little hazy to analysts, and still many people are thinking over and surprising at how quickly these biologic knockoffs can muscle aside some powerhouse competition from well-known brands. In Asia,
.png)
For Patients’ Good or Company Rival: The Petition of TEVA to FDA on Biogen Idec
Several days ago, Teva Pharmaceutical Industries Ltd, which has the market-leading multiple sclerosis drug Copaxone, handed a petition to the U.S. FDA. In the petition, Teva asked FDA to, if possible, delay the market entry of Biogen Idec Inc.’s new MS drug until its safety has been
Collaboration between Bio Service Provider and Biotech Company on Biospecific Cancer Antibodies
On Jan. 14, 2013, OcellO B.V., providing drug discovery screening services with its 3D cell culture-based screening platform, and Merus B.V., a biotech company, like Creative BioMart, offering specific antibodies and recombinant antibodies to help research, have entered into collaboration. In
The 5th Immunotherapeutics & Immunomonitoring Conference
When 31 Jan 2013 to 01 Feb 2013 Where The Westin Gaslamp Quarter, San Diego, United States Introduction Immunology is a broad branch of biomedical science that covers the study of all aspects of the immune system in all organisms. It deals with the physiological functioning of the immune
The New Round of Worldwide Biotech Companies’ Executives
ImmunoCellular Therapeutics ($IMUC) announced Gary S. Titus joined the company's Board of Directors. Titus now works as senior vice president and CFO of SciClone Pharmaceuticals ($SCLN). Coronado Biosciences ($CNDO) tapped Harlan F. Weisman as the company's new chairman and CEO. Weisman has been
Company Acquire: In Face with So Many Suitors, Bausch & Lomb Will Belong to Whom?
According to Bloomberg, the private drug and device company Bausch & Lomb Company, which is owned by private equity Warburg Pincus, recently was fiercely chased by many giants, such as by Abbott Laboratories (ABT), Johnson & Johnson (JNJ), Sanofi and others. Warburg, working with
A New Effective and Accurate New Technology to Edit genome was Found by MIT and Published on Science Online
On the online edition of Science, you will find a report said that researchers from MIT, the Broad Institute and Rockefeller University have developed a new technique for precisely altering the genomes of living cells by adding or deleting genes. This will benefit any research that correlates with
The 2013 Biggest and Most Comprehensive Event for the Vaccine Industry—the 13th Annual World Vaccine Congress & Expo
When From April 16 to April 18, 2013 Where Gaylord National Hotel & Convention Center, Maryland MD, US Introduction The 2013 World Vaccine Congress & Expo is the 13th annual meeting. It is the world's biggest and most comprehensive event for the vaccine industry. The
A New Patent of Monoclonal Antibodies for the Treatment of Serious Diseases Research and Development Registered
On Dec. 21, 2012, one of our peer companies, Immunomedics, Inc. (Nasdaq:IMMU) announced that it has received notice its patent application for "Anti-CD19 antibodies" which would be issued as US patent No. 8,337,840 on Dec. 25, 2012. IMMU primarily attaches importance to the development
The Last FDA Approvals in 2012 for World Pharma Regulatory Blockbusters (From Dec. 21 to Dec. 31)
On Dec. 31, 2012, the last day of the year, the FDA came through with a rapid-fire approval of Johnson & Johnson's bedaquiline, the first new treatment for drug-resistant tuberculosis in four decades. The approval was based on mid-stage data after J&J ($JNJ) made its case that the urgent
Worldwide Blockbusters’ Movements (Alliance and Collaboration within this December)
On Dec. 20, 2012, CEVEC Pharmaceuticals (“CEVEC”), the developer of a novel human expression system derived from amniocytes, and Yuhan Corporation (“Yuhan”) based in Seoul, South Korea announced the signing of a CAP-Technology license agreement. The license will enable Yuhan
World Pharma/Clinical Trial Regulatory (On Dec. 14)
On Dec. 14, 2012, Pfizer Inc. (PFE) and Ligand Pharmaceuticals Incorporated (LGND) announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized
The 2nd Annual Cell Culture World Congress USA in Boston
Introduction The 2nd annual Cell Culture World Congress USA is North America's leading conference focused on the optimization and development of cell culture bioproduction. This is a chance for biopharma, biotechs, biomanufacturing and process experts come to debate advances in cell culture
Company Acquire: Amgen Acquired DeCODE Genetics for $415M Which Is Supposed To Be Closed at the End of 2012
Amgen has planned to acquire Iceland-based DeCODE Genetics which is currently owned by Saga Investments, a consortium including Polaris Venture Partners and ARCH Venture Partners, but later out of bankruptcy in 2010, for $415 million cash, aiming in the biotech pioneer’s presence in
Worldwide Blockbusters' Movements (Alliance and Collaboration within this December)
On Dec. 20, 2012, CEVEC Pharmaceuticals ("CEVEC"), the developer of a novel human expression system derived from amniocytes, and Yuhan Corporation ("Yuhan") based in Seoul, South Korea announced the signing of a CAP-Technology license agreement. The license will enable Yuhan to
2012 Trends and Highlights in Biology Industry
What’s the most popular in 2012 in biology industry? With the approaching of 2013, here the following we picked ten trends and highlights from the perspective of un-professional, let see them together: 1. Human Origins and Evolution: Several different studies highlight ongoing research on
Conference on 2013 Chromosomal-related
We are delight to introduce that our peer company Abcam will held the Chromatin, Replication and Chromosomal Stability 2013 conference to promote industry advance. The following are the related information: When From June 17 to June 19, 2013 Where Biotech Research & Innovation
Drug Safety: the Glass Found in Ranbaxy's Generic Lipitor and Different Parties' Response
In terms of the foreign particles found in the glass-lined reactors at an active pharmaceutical ingredient plant in Toanasa, India in Nov. this year, Ranbaxy Laboratories' recall of generic Lipitor has spawned its first legal repercussion. Then the company notified FDA this fact and the foreign
pSivida's Fluocinolone Insert Iluvien Get Negative Response in U.K. and U.S.
Iluvien, a fluocinolone insert for the treatment of vision loss in diabetes, developed using pSivida's Durasert technology and later its licensee was gained by Alimera Sciences, is an injectable microinsert which delivers the drug into the back of the eye for up to three years to treat chronic
FDA Nod for the First Drug-eluting Stent to Treat Peripheral Arterial Disease
On Nov. 15, 2012, The U.S. Food and Drug Administration (FDA) approved the Zilver PTX Drug-Eluting Peripheral Stent (Zilver PTX Stent) to treat peripheral artery disease (PAD) symptoms. This is the first drug-eluting stent to treat PAD. PAD is a progressive process that fatty material (plaque)
The Sapien Artificial Heart Valve of Edwards get Extra Indications by FDA
Before Oct. 19, 2012, patients with aortic valve stenosis who are eligible for surgery but at high risk for serious surgical complications or death were not allowed to use artificial heart valve. While after the day, they could use Sapien Transcatheter Heart Valve (THV) since the U.S. Food and
World Pharma/Clinical Trial Regulatory (From Nov. 29 to Nov. 30)
On Nov. 30, 2012, Exelixis, Inc. (EXEL) announced that the U.S. Food and Drug Administration (FDA) have approved COMETRIQ™ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC). COMETRIQ is an inhibitor of multiple receptor tyrosine kinases involved in
Begin to Prepare for the Molecular Diagnostics
The 2013 Molecular Diagnostics World Congress Introduction: The research scope of molecular diagnostics captures the genome expression and proteins expression patterns and uses them to differentiate between what is normal and abnormal. Scientist and practitioners have created and developed
Worldwide Biotech/Biopharma Alliance (during Nov. 14 and Nov. 12)
On Nov. 14, 2012, Fujifilm Diosynth Biotechnologies added another licensed product to its list of commercial biopharmaceutical products, following the announcement that ThromboGenics' has received FDA approval for the launch of JETREA? (ocriplasmin) in the USA for the treatment of Symptomatic
